Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.29 HKD | -0.56% | +4.13% | +3.12% |
Apr. 24 | China Resources Pharmaceutical Group Limited Announces Change of Company Secretary | CI |
Apr. 18 | China Resources Pharma Unit Issues 3 Billion Yuan Bonds | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The stock, which is currently worth 2024 to 0.24 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.12% | 4.27B | B | ||
+32.95% | 700B | C+ | ||
-4.97% | 358B | C+ | ||
+18.83% | 330B | B- | ||
+3.54% | 287B | C+ | ||
+15.70% | 236B | B+ | ||
+6.68% | 202B | B- | ||
-9.08% | 197B | A+ | ||
+6.70% | 161B | C+ | ||
-1.81% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3320 Stock
- Ratings China Resources Pharmaceutical Group Limited